ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Bio-Rad Laboratories's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was 1.26%.
As of today (2026-06-25), Bio-Rad Laboratories's WACC % is 10.17%. Bio-Rad Laboratories's ROC % is 2.14% (calculated using TTM income statement data).
Bio-Rad Laboratories earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Bio-Rad Laboratories (FRA:BUWA) ROC % Explanation
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Bio-Rad Laboratories's WACC % is 10.17%. Bio-Rad Laboratories's ROC % is 2.14% (calculated using TTM income statement data).
Bio-Rad Laboratories earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is four times the quarterly (Mar. 2026) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories (FRA:BUWA) has a ROC % of 1.26% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Bio-Rad Laboratories and its competitors.
Is Bio-Rad Laboratories' ROC % too high?
Bio-Rad Laboratories' current ROC % is 1.26%. The Medical Devices & Instruments industry median ROC % is 1.27. Bio-Rad Laboratories' value of 1.26% is 0.8% below this industry median. Overall, Bio-Rad Laboratories has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' ROC % compare to BRKR and MASI?
Bio-Rad Laboratories' ROC % of 1.26% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROC % is 1.27. Bio-Rad Laboratories' value of 1.26% is 0.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Medical Devices & Instruments company?
The median ROC % among Medical Devices & Instruments companies is 1.27, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Rad Laboratories's current ROC % of 1.26% is 0.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Bio-Rad Laboratories and its competitors. For the Medical Devices & Instruments industry, the median ROC % is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Rad Laboratories's current ROC % is 1.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Modestly Undervalued. The stock's GF Value™ is €272.83, compared to a current price of €246.00 — trading 9.8% below its estimated fair value. The current ROC % is 1.26% and 0.8% below the Medical Devices & Instruments industry median of 1.27. Bio-Rad Laboratories' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current ROC % is 1.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued.
The current stock price of €246.00 is trading 9.8% below its estimated GF Value™ of €272.83.
GuruFocus considers Bio-Rad Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:BUWA:
ROC %: 1.26%
GF Value™: €272.83 vs. price of €246.00 (9.8% below fair value)
Industry Position: 0.8% below the Medical Devices & Instruments median
No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
72GF Score
Get the complete analysis for FRA:BUWA
ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BUWA has been successfully added to your 
